Pharmalive - The Pulse of the Pharmaceutical Industry


Search Criteria: Search In:  
Conferences
Hepatic Impairment Studies in Early Development

Hepatic impairment trials are generally included as part of the clinical development of a drug.  This whitepaper, based on years of experience executing hepatic trials, provides practical information for pharma and biotech professionals.  In this whitepaper, you’ll gain knowledge of: 

- Similarities and differences between FDA and EMEA guidance on hepatic trials.

- Categorization standards for hepatic trials.

- Solutions and guidance for those conducting hepatic trials.


Provided by: PRA International
Register or Login below to download this and other white papers.
Login to download whitepapers Register To Download Whitepapers
 
Ask The Experts

MedAdNews
Which pharma or biotech company, in your opinion, uses offshoring ...

R&D Directions
What are some recommendations on "fit-for-purpose" best practices ...
How feasible is the nasal route to deliver peptides into the brain ...
Have tangible strides been made in using PET scanning to study ...

Supplements

MedAdNews
Guide to Pharmaceutical Marketing and Interactive Services
Download

Podcasts

BIO’s Big Ideas with James C. Greenwood
Download

The Government and Drug Development with James C. Greenwood
Download

Politics, Approvals, and PhRMA’s Future with John Castellani
Download

Meet Your New President with John Castellani
Download

Download previous episodes

Webcasts

Pharmalot
Infusing Your Knowledge Of The Injectable Drug Delivery Market
May 23, 2011 2:00pm ET | 11:00AM PT
Register Now

View More Webcasts

If you would like to post your white paper on PharmaLive, please contact us.

 


©2010 UBM Canon Pharmaceutical Media Group